3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
113
Lymphoma, Mantle-Cell
65
Lymphoma, Large B-Cell, Diffuse
40
Lymphoma, Non-Hodgkin
31
Lymphoma, Follicular
30
Waldenstrom Macroglobulinemia
29
Lymphoma
29
Lymphoma, B-Cell
22
Recurrence
21
Lymphoma, B-Cell, Marginal Zone
19
Neoplasms
16
Leukemia
14
Leukemia, B-Cell
10
Multiple Myeloma
9
Bronchiolitis Obliterans Syndrome
9
Leukemia, Lymphoid
8
Burkitt Lymphoma
8
Hematologic Neoplasms
7
Leukemia, Myeloid, Acute
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Hodgkin Disease
5
Leukemia, Prolymphocytic
4
Graft vs Host Disease
4
Lymphoproliferative Disorders
3
Lymphatic Diseases
3
Leukemia, Hairy Cell
3
Immunoproliferative Disorders
3
Immune System Diseases
3
Hematologic Diseases
3
Chromosome 17 deletion
3
Interventions
Cyclophosphamide
22
blinatumomab
18
Cytarabine
15
fludarabine
13
Azacitidine
12
venetoclax
10
fludarabine phosphate
10
Rituximab
8
Lenalidomide
7
Dexamethasone
7
Methotrexate
6
Daunorubicin
6
Mercaptopurine
5
daratumumab
4
Whole-Body Irradiation
4
Vincristine
4
Melphalan
4
Idarubicin
4
Etoposide
4
Busulfan
4
pembrolizumab
3
obinutuzumab
3
Radiotherapy
3
Maintenance
3
Immunotherapy, Adoptive
3
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Drug Therapy
3
Cladribine
3
Asparaginase
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasm, Residual
×
ibrutinib
×
Clear all
NCT02666898
2025-11-26
ICLL07GAI
French Innovative Leukemia Organisation
Phase 2
Completed
135 enrolled